AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 32 min read$EW

Edwards' TAVR Cuts Risk Of Death Or Heart Failure Events In Moderate Aortic Stenosis Trial

Edwards Lifesciences (EW) reported Phase 3 PROGRESS trial results showing TAVR reduced risk of death or heart failure by 33% over 2 years vs. surveillance in moderate aortic stenosis patients. TAVR also improved quality of life and had a favorable safety profile. The trial enrolled 744 patients across 74 sites. EW stock closed at $93.26, up 1.36%.

Original reporting
rttnews.com
Published Nov 3, 2026, 4:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Edwards' TAVR Cuts Risk Of Death Or Heart Failure Events In Moderate Aortic Stenosis Trial — source image
Source · rttnews.com
Decision brief

The 30-second read

$EWBullishHigh
01

Why it matters

The data represent the first robust evidence that early TAVR improves outcomes in moderate aortic stenosis, likely expanding the addressable patient pool.

02

Market read

First‑time release of pivotal trial data that could shift treatment standards and drive revenue growth for EW.

03

What to watch

Potential regulatory review timelines and competition from emerging valve technologies could temper upside.

Relevance 9/10Novelty 9/10Timing: today, pre‑market

Background

The PROGRESS trial, a multicenter Phase 3 study of Edwards' SAPIEN 3 valve, was presented at the TCT 2026 meeting and published in NEJM.

Company-level read

Ticker impact

$EWBullishHigh confidence
Context

Edwards Lifesciences reported Phase 3 PROGRESS trial results showing a 33% reduction in death or heart‑failure events with TAVR versus surveillance.

Expected impact

upward pressure as investors price in broader use of the SAPIEN 3 valve.

Evidence & confidence

First‑time disclosure of statistically significant clinical benefit; market typically rewards such breakthroughs.

Market effects

Sector

May accelerate adoption of transcatheter valve therapies across the cardiovascular device sector.

Regional

U.S. and European med‑tech markets could see modest gains as investors reassess pipeline valuations.

Global

Positive data could influence global heart‑disease treatment guidelines, supporting broader demand.

Counterpoint

What could challenge this read

If reimbursement or procedural costs remain high, the clinical benefit may not translate into immediate sales growth.

Key entities

  • company
    Edwards Lifesciences

    Manufacturer of the SAPIEN 3 transcatheter valve.

  • event
    TCT 2026

    Transcatheter Cardiovascular Therapeutics conference where results were unveiled.

Read at source← All news

StoryEdwards TAVR halves heart‑failure hospitalizations in moderate aortic stenosis trial

Also covered by

2 outlets

Related articles

NOV 3
$EWMedAI 8/10

Edwards' PASCAL System Improves Outcomes And Quality Of Life In Tricuspid Valve Disease Trial

Edwards Lifesciences (EW) reported positive results from its CLASP II TR trial, showing that the PASCAL system improved outcomes in tricuspid regurgitation patients. After one year, 80% of patients treated with the PASCAL system achieved moderate or less severe tricuspid regurgitation, compared with 30% in the control group. The company plans to announce Q3 2026 results on November 4, 2026, and EW stock closed at $93.26, up 1.36%.

rttnews.com2 min
NOV 3
$EWMedAI 8/10

Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits

Edwards Lifesciences reported positive results from two trials. The PASCAL CLASP IITR trial showed patients treated with PASCAL had nearly twice the benefit of those with medical therapy alone, with 80% having moderate or less tricuspid regurgitation at one year. The PROGRESS trial found TAVR reduced the two-year risk of death or heart-failure events by 33% in selected patients with moderate aortic stenosis.

finance.yahoo.com1 min
NOV 2
$EWMedAI 8/10

Edwards PASCAL system shows superiority in tricuspid repair trial

Edwards Lifesciences (NYSE:EW) reported that its PASCAL system for tricuspid repair met its primary endpoint in the CLASP II TR trial, showing 80% of patients achieved moderate or less regurgitation at one year, compared to 30% in the control group. The trial also showed an 18-point improvement in quality-of-life measures. The PASCAL system received FDA approval in October 2026 and has been used to treat thousands of patients worldwide, according to the company.

investing.com2 min
NOV 2
$EWMedAI 8/10

After a year, 80% had moderate-or-less valve leakage with a repair device, versus 30% on medication.

Edwards Lifesciences (EW) announced positive one-year results from the CLASP II TR trial, showing 80% of patients treated with the PASCAL system had moderate or less valve leakage, compared to 30% on medication alone. The data, presented at TCT, demonstrated reduced tricuspid regurgitation and improved health status. The PASCAL system received FDA approval in October 2026 and CE Mark in 2020, with thousands of patients treated worldwide.

stocktitan.net2 min